Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention†Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami ...

Marzia Lotrionte, Giuseppe G L Biondi-Zoccai, Pierfrancesco Agostoni, Antonio Abbate, Dominick J. Angiolillo, Marco Valgimigli, Claudio Moretti, Emanuele Meliga, Thomas Cuisset, Marie Christine Alessi, Gilles Montalescot, Jean Philippe Collet, Germano Di Sciascio, Ron Waksman, Luca Testa, Giuseppe Sangiorgi, Antonio Laudito, Gian P. Trevi, Imad Sheiban

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Full text: Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention†Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida. Combined antiplatelet treatment with aspirin and clopidogrel is pivotal to minimize periprocedural adverse events in patients who undergo percutaneous coronary intervention. However, there is debate on the best clopidogrel loading dose. The investigators performed a systematic review and meta-analysis of the optimal clopidogrel loading dose. Pertinent trials comparing high (>300 mg) and standard (300 mg) clopidogrel loading doses in patients scheduled for catheterization and/or percutaneous coronary intervention were systematically searched in BioMedCentral, CENTRAL, Google Scholar, and PubMed (December 2006). The primary end point was the 1-month rate of death or myocardial infarction. Secondary end points included other ischemic and bleeding adverse effects. Peto odds ratios were computed. A total of 10 studies (7 randomized, 3 nonrandomized) were included, enrolling 1,567 patients (712 loaded with 300 mg, 11 with 450 mg, 790 with 600 mg, and 54 with 900 mg). Overall, a high loading dose proved significantly superior to a standard loading dose in preventing cardiac death or nonfatal myocardial infarction (odds ratio 0.54, 95% confidence interval 0.32 to 0.90, p = 0.02), without any statistically significant increase in major or minor bleedings (p = 0.55 and p = 0.98, respectively). Sensitivity analysis restricted to randomized trials confirmed the superiority of a high loading dose regimen (p = 0.0031). Meta-regression disclosed a significant interaction between event rate and the benefits of high loading doses (p = 0.005), suggesting that the greater the underlying risk, the greater the favorable impact of a high loading dose. In conclusion, a high clopidogrel loading dose (>300 mg) significantly reduces early ischemic events in patients scheduled for percutaneous coronary intervention.

Original languageEnglish
Pages (from-to)1199-1206
Number of pages8
JournalThe American Journal of Cardiology
Volume100
Issue number8
DOIs
Publication statusPublished - Oct 15 2007

Fingerprint

clopidogrel
Paris
Consultants
France
Meta-Analysis
Percutaneous Coronary Intervention
Odds Ratio
Myocardial Infarction
Hemorrhage
PubMed
Catheterization
Aspirin
Research Personnel
Confidence Intervals

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention†Conflicts of interest : Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami ... / Lotrionte, Marzia; Biondi-Zoccai, Giuseppe G L; Agostoni, Pierfrancesco; Abbate, Antonio; Angiolillo, Dominick J.; Valgimigli, Marco; Moretti, Claudio; Meliga, Emanuele; Cuisset, Thomas; Alessi, Marie Christine; Montalescot, Gilles; Collet, Jean Philippe; Di Sciascio, Germano; Waksman, Ron; Testa, Luca; Sangiorgi, Giuseppe; Laudito, Antonio; Trevi, Gian P.; Sheiban, Imad.

In: The American Journal of Cardiology, Vol. 100, No. 8, 15.10.2007, p. 1199-1206.

Research output: Contribution to journalArticle

Lotrionte, Marzia ; Biondi-Zoccai, Giuseppe G L ; Agostoni, Pierfrancesco ; Abbate, Antonio ; Angiolillo, Dominick J. ; Valgimigli, Marco ; Moretti, Claudio ; Meliga, Emanuele ; Cuisset, Thomas ; Alessi, Marie Christine ; Montalescot, Gilles ; Collet, Jean Philippe ; Di Sciascio, Germano ; Waksman, Ron ; Testa, Luca ; Sangiorgi, Giuseppe ; Laudito, Antonio ; Trevi, Gian P. ; Sheiban, Imad. / Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention†Conflicts of interest : Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami ... In: The American Journal of Cardiology. 2007 ; Vol. 100, No. 8. pp. 1199-1206.
@article{c73f800dddbf4b56b90973ff037149d8,
title = "Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami ...",
abstract = "Full text: Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida. Combined antiplatelet treatment with aspirin and clopidogrel is pivotal to minimize periprocedural adverse events in patients who undergo percutaneous coronary intervention. However, there is debate on the best clopidogrel loading dose. The investigators performed a systematic review and meta-analysis of the optimal clopidogrel loading dose. Pertinent trials comparing high (>300 mg) and standard (300 mg) clopidogrel loading doses in patients scheduled for catheterization and/or percutaneous coronary intervention were systematically searched in BioMedCentral, CENTRAL, Google Scholar, and PubMed (December 2006). The primary end point was the 1-month rate of death or myocardial infarction. Secondary end points included other ischemic and bleeding adverse effects. Peto odds ratios were computed. A total of 10 studies (7 randomized, 3 nonrandomized) were included, enrolling 1,567 patients (712 loaded with 300 mg, 11 with 450 mg, 790 with 600 mg, and 54 with 900 mg). Overall, a high loading dose proved significantly superior to a standard loading dose in preventing cardiac death or nonfatal myocardial infarction (odds ratio 0.54, 95{\%} confidence interval 0.32 to 0.90, p = 0.02), without any statistically significant increase in major or minor bleedings (p = 0.55 and p = 0.98, respectively). Sensitivity analysis restricted to randomized trials confirmed the superiority of a high loading dose regimen (p = 0.0031). Meta-regression disclosed a significant interaction between event rate and the benefits of high loading doses (p = 0.005), suggesting that the greater the underlying risk, the greater the favorable impact of a high loading dose. In conclusion, a high clopidogrel loading dose (>300 mg) significantly reduces early ischemic events in patients scheduled for percutaneous coronary intervention.",
author = "Marzia Lotrionte and Biondi-Zoccai, {Giuseppe G L} and Pierfrancesco Agostoni and Antonio Abbate and Angiolillo, {Dominick J.} and Marco Valgimigli and Claudio Moretti and Emanuele Meliga and Thomas Cuisset and Alessi, {Marie Christine} and Gilles Montalescot and Collet, {Jean Philippe} and {Di Sciascio}, Germano and Ron Waksman and Luca Testa and Giuseppe Sangiorgi and Antonio Laudito and Trevi, {Gian P.} and Imad Sheiban",
year = "2007",
month = "10",
day = "15",
doi = "10.1016/j.amjcard.2007.05.048",
language = "English",
volume = "100",
pages = "1199--1206",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest

T2 - Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami ...

AU - Lotrionte, Marzia

AU - Biondi-Zoccai, Giuseppe G L

AU - Agostoni, Pierfrancesco

AU - Abbate, Antonio

AU - Angiolillo, Dominick J.

AU - Valgimigli, Marco

AU - Moretti, Claudio

AU - Meliga, Emanuele

AU - Cuisset, Thomas

AU - Alessi, Marie Christine

AU - Montalescot, Gilles

AU - Collet, Jean Philippe

AU - Di Sciascio, Germano

AU - Waksman, Ron

AU - Testa, Luca

AU - Sangiorgi, Giuseppe

AU - Laudito, Antonio

AU - Trevi, Gian P.

AU - Sheiban, Imad

PY - 2007/10/15

Y1 - 2007/10/15

N2 - Full text: Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida. Combined antiplatelet treatment with aspirin and clopidogrel is pivotal to minimize periprocedural adverse events in patients who undergo percutaneous coronary intervention. However, there is debate on the best clopidogrel loading dose. The investigators performed a systematic review and meta-analysis of the optimal clopidogrel loading dose. Pertinent trials comparing high (>300 mg) and standard (300 mg) clopidogrel loading doses in patients scheduled for catheterization and/or percutaneous coronary intervention were systematically searched in BioMedCentral, CENTRAL, Google Scholar, and PubMed (December 2006). The primary end point was the 1-month rate of death or myocardial infarction. Secondary end points included other ischemic and bleeding adverse effects. Peto odds ratios were computed. A total of 10 studies (7 randomized, 3 nonrandomized) were included, enrolling 1,567 patients (712 loaded with 300 mg, 11 with 450 mg, 790 with 600 mg, and 54 with 900 mg). Overall, a high loading dose proved significantly superior to a standard loading dose in preventing cardiac death or nonfatal myocardial infarction (odds ratio 0.54, 95% confidence interval 0.32 to 0.90, p = 0.02), without any statistically significant increase in major or minor bleedings (p = 0.55 and p = 0.98, respectively). Sensitivity analysis restricted to randomized trials confirmed the superiority of a high loading dose regimen (p = 0.0031). Meta-regression disclosed a significant interaction between event rate and the benefits of high loading doses (p = 0.005), suggesting that the greater the underlying risk, the greater the favorable impact of a high loading dose. In conclusion, a high clopidogrel loading dose (>300 mg) significantly reduces early ischemic events in patients scheduled for percutaneous coronary intervention.

AB - Full text: Meta-Analysis Appraising High Clopidogrel Loading in Patients Undergoing Percutaneous Coronary Intervention††Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida. Combined antiplatelet treatment with aspirin and clopidogrel is pivotal to minimize periprocedural adverse events in patients who undergo percutaneous coronary intervention. However, there is debate on the best clopidogrel loading dose. The investigators performed a systematic review and meta-analysis of the optimal clopidogrel loading dose. Pertinent trials comparing high (>300 mg) and standard (300 mg) clopidogrel loading doses in patients scheduled for catheterization and/or percutaneous coronary intervention were systematically searched in BioMedCentral, CENTRAL, Google Scholar, and PubMed (December 2006). The primary end point was the 1-month rate of death or myocardial infarction. Secondary end points included other ischemic and bleeding adverse effects. Peto odds ratios were computed. A total of 10 studies (7 randomized, 3 nonrandomized) were included, enrolling 1,567 patients (712 loaded with 300 mg, 11 with 450 mg, 790 with 600 mg, and 54 with 900 mg). Overall, a high loading dose proved significantly superior to a standard loading dose in preventing cardiac death or nonfatal myocardial infarction (odds ratio 0.54, 95% confidence interval 0.32 to 0.90, p = 0.02), without any statistically significant increase in major or minor bleedings (p = 0.55 and p = 0.98, respectively). Sensitivity analysis restricted to randomized trials confirmed the superiority of a high loading dose regimen (p = 0.0031). Meta-regression disclosed a significant interaction between event rate and the benefits of high loading doses (p = 0.005), suggesting that the greater the underlying risk, the greater the favorable impact of a high loading dose. In conclusion, a high clopidogrel loading dose (>300 mg) significantly reduces early ischemic events in patients scheduled for percutaneous coronary intervention.

UR - http://www.scopus.com/inward/record.url?scp=34948852426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34948852426&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2007.05.048

DO - 10.1016/j.amjcard.2007.05.048

M3 - Article

C2 - 17920357

AN - SCOPUS:34948852426

VL - 100

SP - 1199

EP - 1206

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 8

ER -